Vertex Pharmaceuticals (VRTX) Ascends But Remains Behind Market: Some Facts to Note
Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $541
Vertex Pharmaceuticals Price Target Lowered to $541 From $550 at BofA
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
Capricor Reports Positive Long-term Data for DMD Drug Deramiocel
